Ovid Therapeutics posts earnings beat, revenue tops estimates
Pharmaceutical firm reports adjusted loss per share of $0.04, beating expectations, while revenue exceeded analyst forecasts.
Ovid Therapeutics reported adjusted earnings that exceeded expectations for the latest quarter, with a loss per share of $0.04 compared to the anticipated $0.08. Revenue also surpassed estimates, totaling $12.3 million versus the projected $10.5 million.
The New York-based biopharmaceutical company, focused on treatments for rare neurological disorders, attributed the better-than-expected performance to higher-than-anticipated product sales and operational efficiencies. Ovid’s lead drug candidate, OV101, remains under regulatory review for potential approval in multiple indications.
Analysts highlighted the revenue beat as a positive sign, though they cautioned that the company’s path to profitability remains uncertain given ongoing research and development investments. Shares of Ovid were up 5% in premarket trading following the results.
Ovid Therapeutics did not provide updated guidance for the full year, stating that it would evaluate its financial outlook in light of recent developments, including regulatory timelines and commercialization strategies.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →